BCRX vs. CHCI

Last updated Apr 1, 2026

Compare and contrast key facts about BioCryst Pharmaceuticals, Inc. (BCRX) and Comstock Holding Companies, Inc. (CHCI).

Performance

BCRX vs. CHCI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BioCryst Pharmaceuticals, Inc. (BCRX) and Comstock Holding Companies, Inc. (CHCI). The values are adjusted to include any dividend payments, if applicable.

BCRX vs. CHCI - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
BCRX BioCryst Pharmaceuticals, Inc.	22.05%	3.72%	25.54%	-47.82%	-17.11%	85.91%	115.94%	-57.25%	64.36%	-22.43%
CHCI Comstock Holding Companies, Inc.	62.99%	43.81%	82.32%	4.28%	-12.37%	53.00%	62.02%	16.46%	-1.18%	-5.56%

Fundamentals

EPS BCRX : $1.20 CHCI : $1.33
PE Ratio BCRX : 7.93 CHCI : 14.26
PS Ratio BCRX : 2.39 CHCI : 3.55
Total Revenue (TTM) BCRX : $874.84M CHCI : $55.84M
Gross Profit (TTM) BCRX : $855.43M CHCI : $11.93M
EBITDA (TTM) BCRX : $345.49M CHCI : $10.21M

Returns By Period

In the year-to-date period, BCRX achieves a 22.05% return, which is significantly lower than CHCI's 62.99% return. Over the past 10 years, BCRX has underperformed CHCI with an annualized return of 12.90%, while CHCI has yielded a comparatively higher 26.89% annualized return.

BCRX

• 1D: 0.74%
• 1M: 8.80%
• YTD: 22.05%
• 6M: 25.43%
• 1Y: 26.93%
• 3Y*: 4.51%
• 5Y*: -0.88%
• 10Y*: 12.90%

CHCI

• 1D: 6.46%
• 1M: 62.30%
• YTD: 62.99%
• 6M: 35.19%
• 1Y: 119.72%
• 3Y*: 55.16%
• 5Y*: 26.97%
• 10Y*: 26.89%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BCRX vs. CHCI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BCRX

BCRX Risk / Return Rank: 57
BCRX Sharpe Ratio Rank: 61
BCRX Sortino Ratio Rank: 63
BCRX Omega Ratio Rank: 58
BCRX Calmar Ratio Rank: 53
BCRX Martin Ratio Rank: 50

CHCI

CHCI Risk / Return Rank: 82
CHCI Sharpe Ratio Rank: 87
CHCI Sortino Ratio Rank: 85
CHCI Omega Ratio Rank: 82
CHCI Calmar Ratio Rank: 79
CHCI Martin Ratio Rank: 73

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BCRX vs. CHCI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BioCryst Pharmaceuticals, Inc. (BCRX) and Comstock Holding Companies, Inc. (CHCI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BCRX	CHCI	Difference
Sharpe ratio Return per unit of total volatility	0.53	1.72	-1.18
Sortino ratio Return per unit of downside risk	1.29	2.43	-1.14
Omega ratio Gain probability vs. loss probability	1.14	1.31	-0.16
Calmar ratio Return relative to maximum drawdown	0.48	2.25	-1.77
Martin ratio Return relative to average drawdown	0.77	4.23	-3.46
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BCRX vs. CHCI - Sharpe Ratio Comparison

The current BCRX Sharpe Ratio is 0.53, which is lower than the CHCI Sharpe Ratio of 1.72. The chart below compares the historical Sharpe Ratios of BCRX and CHCI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	BCRX	CHCI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.53	1.72	-1.18
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.01	0.43	-0.45
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.18	0.29	-0.11
Sharpe Ratio (All Time) Calculated using the full available price history	0.01	-0.06	+0.08

Correlation

The correlation between BCRX and CHCI is 0.08, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

BCRX vs. CHCI - Dividend Comparison

Neither BCRX nor CHCI has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

BCRX vs. CHCI - Drawdown Comparison

The maximum BCRX drawdown since its inception was -97.74%, roughly equal to the maximum CHCI drawdown of -99.80%. Use the drawdown chart below to compare losses from any high point for BCRX and CHCI.

Drawdown Indicators

	BCRX	CHCI	Difference
Max Drawdown Largest peak-to-trough decline	-97.74%	-99.80%	+2.06%
Max Drawdown (1Y) Largest decline over 1 year	-44.24%	-44.23%	-0.01%
Max Drawdown (5Y) Largest decline over 5 years	-79.10%	-51.18%	-27.92%
Max Drawdown (10Y) Largest decline over 10 years	-83.69%	-75.34%	-8.35%
Current Drawdown Current decline from peak	-71.26%	-90.89%	+19.63%
Average Drawdown Average peak-to-trough decline	-69.63%	-92.10%	+22.47%
Ulcer Index Depth and duration of drawdowns from previous peaks	27.45%	23.56%	+3.89%

Volatility

BCRX vs. CHCI - Volatility Comparison

The current volatility for BioCryst Pharmaceuticals, Inc. (BCRX) is 15.92%, while Comstock Holding Companies, Inc. (CHCI) has a volatility of 24.22%. This indicates that BCRX experiences smaller price fluctuations and is considered to be less risky than CHCI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BCRX	CHCI	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.92%	24.22%	-8.30%
Volatility (6M) Calculated over the trailing 6-month period	34.22%	46.18%	-11.96%
Volatility (1Y) Calculated over the trailing 1-year period	50.81%	70.73%	-19.92%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	63.41%	62.62%	+0.79%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	72.94%	93.08%	-20.14%

Financials

BCRX vs. CHCI - Profitability Comparison

The chart below illustrates the profitability comparison between BioCryst Pharmaceuticals, Inc. and Comstock Holding Companies, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

BCRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, BioCryst Pharmaceuticals, Inc. reported a gross profit of 397.03M and revenue of 406.56M. Therefore, the gross margin over that period was 97.7%.

CHCI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Comstock Holding Companies, Inc. reported a gross profit of 1.46M and revenue of 13.32M. Therefore, the gross margin over that period was 11.0%.

BCRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, BioCryst Pharmaceuticals, Inc. reported an operating income of 260.39M and revenue of 406.56M, resulting in an operating margin of 64.1%.

CHCI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Comstock Holding Companies, Inc. reported an operating income of 661.00K and revenue of 13.32M, resulting in an operating margin of 5.0%.

BCRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, BioCryst Pharmaceuticals, Inc. reported a net income of 245.85M and revenue of 406.56M, resulting in a net margin of 60.5%.

CHCI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Comstock Holding Companies, Inc. reported a net income of 541.00K and revenue of 13.32M, resulting in a net margin of 4.1%.